Fate Therapeutics Inc
FATE
View Detailed Chart
1.185USD
-0.005-0.42%
Close 01/30, 16:00（ET）Quotes delayed by 15 min
136.67MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-0.42%
5 Days
-5.20%
1 Month
+18.80%
6 Months
+1.28%
Year to Date
+20.60%
1 Year
-9.54%
View Detailed Chart
TradingKey Stock Score of Fate Therapeutics Inc
Currency: USD Updated: 2026-01-29Key Insights
Fate Therapeutics Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 99 out of 393 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 4.94.In the medium term, the stock price is expected to trend down.Despite strong stock market performance and technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Fate Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Fate Therapeutics Inc Highlights
StrengthsRisks
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Growing
The company is in a growing phase, with the latest annual income totaling USD 13.63M.
Overvalued
The company’s latest PE is -0.90, at a high 3-year percentile range.
Held by PRFDX
Star Investor PRFDX holds 10.24K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
4.944
Target Price
+277.44%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Fate Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Fate Therapeutics Inc Info
Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. Using its proprietary iPSC product platform, the Company has established a position in creating multiplexed-engineered master iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Its product candidates under development include FT819, FT522, FT829, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT522 is its first iPSC-derived CAR NK cell product candidate that incorporates its novel Alloimmune Defense Receptor (ADR) technology.
Ticker SymbolFATE
CompanyFate Therapeutics Inc
CEOValamehr (Bahram)
Websitehttps://fatetherapeutics.com/
Related Instruments
+1.35%
-0.00%
+1.15%
+0.19%
-0.15%
+1.88%
+0.17%
-0.28%
+1.74%
+1.36%
-1.17%
+1.79%
+1.40%
+1.87%
+1.11%
+1.60%
-0.99%
0.00%
+2.53%
+0.41%Popular Symbols
259.490
+1.210 (+0.47%)
191.150
-1.360 (-0.71%)
83876.340
-302.610 (-0.36%)
250.310
-28.100 (-10.09%)
2678.220
-125.130 (-4.46%)
430.500
+13.940 (+3.35%)
4846.990
-546.610 (-10.13%)
65.493
+0.255 (+0.39%)
1.185
-0.011 (-0.93%)
154.759
+1.647 (+1.08%)
